One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

"Through detecting particular markers in the blood ... More information: George Seed et al, Elucidating acquired PARP inhibitor resistance in advanced prostate cancer, Cancer Cell (2024).

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for ... naïve metastatic castration-resistant prostate cancer (mCRPC) whose disease ...

So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of poly(ADP-ribose) polymerase (PARP) inhibitors, are only effective in 5% to 7% of patients.

(UroToday.com) Dr. Elena Castro provided a terrific discussion of PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) immediately following the presentation of updated data from ...

While these approaches show promise, ADT remains essential in metastatic castration-resistant prostate cancer (mCRPC), though emerging treatments like bipolar androgen therapy (BAT) may offer future ...

PARP inhibitor treatment can induce various resistance mechanisms, including re-activating BRCA mutations, mutations in HR-inhibiting genes and upregulation of drug efflux pumps. Clinical ...